Race Oncology doses first patient in RC220 trial

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Race Oncology vice president of Medical Dr. Simon Fisher talked with Proactive about the company’s milestone of dosing the first patient in its Phase 1 clinical trial combining RC220 with doxorubicin. The trial targets solid tumours and is designed to address the known cardiovascular toxicity associated with doxorubicin, a commonly used chemotherapy drug.

Fisher explained that many patients benefit from doxorubicin but are often unable to continue due to its damaging effects on the heart. “Given in tandem or together, doxorubicin and RC220 may decrease the onset or diminish the worsening of the cardiovascular system,” he said.

Initial dosing showed no dose-limiting toxicities, with Fisher confirming, “We saw nothing that required the patient to come off the medicine.” This result is significant for a Phase 1 trial focused on safety, especially considering RC220’s expected use over extended treatment periods.

The open-label trial is not confined to Australia. Race Oncology is engaging regulatory bodies in Hong Kong and South Korea and expects to activate sites in both regions shortly. The company also has plans for further studies in the United States and Europe, underlining a strategic global expansion effort.

Fisher emphasised the goal of global accessibility, stating that they aim to enable patients worldwide to benefit from the combination therapy once safety and efficacy are demonstrated.

For more videos from Proactive, don’t forget to like this video, subscribe to the channel, and hit the notification bell to stay updated.

#RaceOncology #RC220 #CancerResearch #Doxorubicin #ClinicalTrials #OncologyNews #PharmaUpdates #BiotechNews #SolidTumorTreatment #Cardiotoxicity #GlobalHealth
Category
Oncology
Be the first to comment

Up Next